



Subject: HER-2 Testing in Gastroesophageal Adenocarcinoma

Articles in Evidence Tables

(Literature search dates: 01/01/2015 – 11/5/2024)

1. Ahn S, Ahn S, Van Vrancken M, et al. Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens. *Oncotarget*. 2015;6(35):38372-38380. doi:10.18632/oncotarget.5368
2. Amato M, Perrone G, Righi D, et al. HER2 status in gastric cancer: Comparison between primary and distant metastatic disease. *Pathol Oncol Res*. 2017;23(1):55-61. doi:10.1007/s12253-016-0082-5
3. Bang K, Cheon J, Park YS, et al. Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab. *Gastric Cancer*. 2022;25(4):794-803. doi:10.1007/s10120-022-01298-6
4. Catenacci DV, Kang YK, Uronis HE, et al. Circulating tumor DNA as a predictive biomarker for clinical outcomes with margetuximab and pembrolizumab in pretreated HER2-positive gastric/ gastroesophageal adenocarcinoma. *Oncology (Williston Park)*. 2023;37(4):176-183. doi:10.46883/2023.25920992
5. Chakrabarti S, Bucheit L, Saha J, et al. HER2-directed therapy following ctDNA-identified ERBB2 amplification in patients with advanced gastroesophageal cancer: Exploration of real-world outcomes. *ESMO Gastrointestinal Oncology*. 2024;4:100056. doi:10.1016/j.esmogo.2024.100056
6. Chan E, Duckworth LV, Alkhasawneh A, et al. Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma. *J Gastrointest Oncol*. 2016;7(2):173-180. doi:10.3978/j.issn.2078-6891.2015.071
7. Choi S, Chu J, Kim B, et al. Tumor heterogeneity index to detect human epidermal growth factor receptor 2 amplification by next-generation sequencing: A direct comparison study with immunohistochemistry. *J Mol Diagn*. 2019;21(4):612-622. doi:10.1016/j.jmoldx.2019.02.007
8. Creemers A, Ebbing EA, Hooijer GKJ, et al. The dynamics of HER2 status in esophageal adenocarcinoma. *Oncotarget*. 2018;9(42):26787-26799. doi:10.18632/oncotarget.25507
9. DiPeri TP, Kong K, Varadarajan K, et al. Discordance of HER2 expression and/or amplification on repeat testing. *Mol Cancer Ther*. 2023;22(8):976-984. doi:10.1158/1535-7163.MCT-22-0630
10. Fazlollahi L, Remotti HE, Iuga A, et al. HER2 heterogeneity in gastroesophageal cancer detected by testing biopsy and resection specimens. *Arch Pathol Lab Med*. 2018;142(4):516-522. doi:10.5858/arpa.2017-0039-OA
11. Freitas MB, Gullo I, Leitao D, et al. HER2 and PD-L1 expression in gastric and gastroesophageal junction cancer: Insights for combinatorial targeting approaches. *Cancers (Basel)*. 2024;16(6):20. doi:10.3390/cancers16061227
12. Gao J, Wang H, Zang W, et al. Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer. *Cancer Sci*. 2017;108(9):1881-1887. doi:10.1111/cas.13314
13. Genc AZ, Koseoglu RD, Arici A, Demir O. HER-2/neu gene analysis on endoscopic biopsy samples and gastric resection materials in gastric carcinomas. *Russian Open Medical Journal*. 2019;8(4). doi:10.15275/rusomj.2019.0410
14. Grenda A, Wojas-Krawczyk K, Skoczylas T, et al. HER2 gene assessment in liquid biopsy of gastric and esophagogastric junction cancer patients qualified for surgery. *BMC Gastroenterol*. 2020;20(1):382. doi:10.1186/s12876-020-01531-5
15. Gulten G, Yilmaz B, Demirkan NC. Comparing human epidermal growth factor receptor 2 amplification and expression using immunohistochemistry and silver in situ hybridisation in gastric carcinoma and lymph node metastasis. *Oncol Lett*. 2020;20(2):1897-1905. doi:10.3892/ol.2020.11731

16. Hashimoto T, Nakamura Y, Mishima S, et al. Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential. *Cancer Sci*. 2024;115(5):1622-1633. doi:10.1111/cas.16109
17. Hedner C, Tran L, Borg D, et al. Discordant human epidermal growth factor receptor 2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis. *Histopathology*. 2016;68(2):230-240. doi:10.1111/his.12744
18. Hoffmann M, Pasch S, Schamberger T, et al. Diagnostic pathology of early systemic cancer: ERBB2 gene amplification in single disseminated cancer cells determines patient survival in operable esophageal cancer. *Int J Cancer*. 2018;142(4):833-843. doi:10.1002/ijc.31108
19. Huang SC, Ng KF, Lee SE, et al. HER2 testing in paired biopsy and excision specimens of gastric cancer: The reliability of the scoring system and the clinicopathological factors relevant to discordance. *Gastric Cancer*. 2016;19(1):176-182. doi:10.1007/s10120-014-0453-0
22. Huber AR, Buscaglia B, Koltz BR, et al. Impact of specimen type and specimen number on HER2 status in gastroesophageal junction and gastric adenocarcinoma. *Am J Clin Pathol*. 2019;151(5):461-468. doi:10.1093/ajcp/aqy166
21. Hyung J, Kim HD, Ryu MH, et al. Gastric cancer HER2 re-assessment study 2 (GASTHER2): HER2 re-assessment for initially HER2-negative advanced gastric cancer patients after progression on first-line treatment. *Cancer Res Treat*. 2024;56(1):199-207. doi:10.4143/crt.2023.490
22. Ichikawa H, Usui K, Aizawa M, et al. Clinical application of targeted tumour sequencing tests for detecting ERBB2 amplification and optimizing anti-HER2 therapy in gastric cancer. *BMC Cancer*. 2024;24(1):719. doi:10.1186/s12885-024-12482-5
23. Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for her2-positive gastric or gastro-oesophageal junction adenocarcinoma: Interim analyses from the phase 3 keynote-811 randomised placebo-controlled trial. *Lancet*. 2023;402(10418):2197-2208. doi:10.1016/S0140-6736(23)02033-0
24. Janjigian YY, Kawazoe A, Yanez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. *Nature*. 2021;600(7890):727-730. doi:10.1038/s41586-021-04161-3
25. Janjigian YY, Maron SB, Chatila WK, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: An open-label, single-arm, phase 2 trial. *Lancet Oncol*. 2020;21(6):821-831. doi:10.1016/S1470-2045(20)30169-8
26. Kanayama K, Imai H, Yoneda M, Hirokawa YS, Shiraishi T. Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization. *Cancer Sci*. 2016;107(4):536-542. doi:10.1111/cas.12886
27. Kannangara DKS, Lokuhetty MDS, Subasinghe D, Gunawardene Y, Dassanayake RS. Could quantitative real-time polymerase chain reaction assay serve as an alternative test method to evaluate human epidermal growth factor receptor 2 status of gastric carcinoma in the South Asian setting? *Indian J Gastroenterol*. 2019;38(4):317-324. doi:10.1007/s12664-019-00955-6
28. Kim B, Nam SK, Seo SH, et al. Comparative analysis of HER2 copy number between plasma and tissue samples in gastric cancer using droplet digital PCR. *Sci Rep*. 2020;10(1):4177. doi:10.1038/s41598-020-60897-4
29. Kim H, Son SM, Woo CG, et al. Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions. *BMC Cancer*. 2019;19(1):834. doi:10.1186/s12885-019-6035-0
30. Kim ST, Banks KC, Pectasides E, et al. Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients. *Ann Oncol*. 2018;29(4):1037-1048. doi:10.1093/annonc/mdy034

31. Klein-Scory S, Ladigan-Badura S, Mika T, et al. Liquid biopsy based HER2 amplification status in gastric cancer patients indicates clinical response. *Heliyon*. 2023;9(11):e21339. doi:10.1016/j.heliyon.2023.e21339
32. Lian J, Zhang G, Zhang Y, et al. PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance. *Dig Liver Dis*. 2022;54(10):1419-1427. doi:10.1016/j.dld.2022.01.128
33. Maron SB, Chase LM, Lomnicki S, et al. Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma. *Clin Cancer Res*. 2019;25(23):7098-7112. doi:10.1158/1078-0432.CCR-19-1704
34. Mikhail S, Ciombor K, Noonan A, et al. Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet? *Oncotarget*. 2015;6(26):22206-22213. doi:10.18632/oncotarget.4247
35. Nergiz D, Alikanoglu AS, Suren D, Gomceli I, Ozturk B. Concordance of HER2 status tested by IHC and FISH in biopsy and surgical resection specimens and comparison with clinicopathological features in gastric carcinoma. *Indian J Pathol Microbiol*. 2022;65(2):321-327. doi:10.4103/IJPM.IJPM_535_20
36. Niu D, Li L, Yu Y, et al. Evaluation of next generation sequencing for detecting HER2 copy number in breast and gastric cancers. *Pathol Oncol Res*. 2020;26(4):2577-2585. doi:10.1007/s12253-020-00844-w
37. Oki E, Okano S, Saeki H, et al. Protein expression of programmed death 1 ligand 1 and HER2 in gastric carcinoma. *Oncology*. 2017;93(6):387-394. doi:10.1159/000479231
38. Park SR, Park YS, Ryu MH, et al. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of gastric cancer HER2 reassessment study 1 (GASTHER1). *Eur J Cancer*. 2016;53:42-50. doi:10.1016/j.ejca.2015.09.018
39. Pectasides E, Stachler MD, Derks S, et al. Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma. *Cancer Discov*. 2018;8(1):37-48. doi:10.1158/2159-8290.CD-17-0395
40. Pereira MA, Ramos M, Dias AR, et al. Expression profile of markers for targeted therapy in gastric cancer patients: HER-2, microsatellite instability and PD-L1. *Mol Diagn Ther*. 2019;23(6):761-771. doi:10.1007/s40291-019-00424-y
41. Pietrantonio F, Caporale M, Morano F, et al. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. *Int J Cancer*. 2016;139(12):2859-2864. doi:10.1002/ijc.30408
42. Ross DS, Zehir A, Cheng DT, et al. Next-generation assessment of human epidermal growth factor receptor 2 (ERBB2) amplification status: Clinical validation in the context of a hybrid capture-based, comprehensive solid tumor genomic profiling assay. *J Mol Diagn*. 2017;19(2):244-254. doi:10.1016/j.jmoldx.2016.09.010
43. Saeki H, Oki E, Kashiwada T, et al. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). *Eur J Cancer*. 2018;105:41-49. doi:10.1016/j.ejca.2018.09.024
44. Saito M, Yamashita K, Arimura Y, et al. Serum HER2 as an adjunct to assess HER2 status for advanced gastric cancer: A prospective multicenter trial (SHERLOCK). *Acta Oncol*. 2016;55(3):309-317. doi:10.3109/0284186X.2015.1107189
45. Saito T, Nakanishi H, Mochizuki Y, et al. Preferential HER2 expression in liver metastases and EGFR expression in peritoneal metastases in patients with advanced gastric cancer. *Gastric Cancer*. 2015;18(4):711-719. doi:10.1007/s10120-014-0417-4
46. Seo S, Ryu MH, Park YS, et al. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: Results of the gastric cancer HER2 reassessment study 3 (GASTHER3). *Gastric Cancer*. 2019;22(3):527-535. doi:10.1007/s10120-018-0891-1

47. Shoda K, Ichikawa D, Fujita Y, et al. Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer. *Gastric Cancer*. 2017;20(1):126-135. doi:10.1007/s10120-016-0599-z
48. Shoda K, Masuda K, Ichikawa D, et al. HER2 amplification detected in the circulating DNA of patients with gastric cancer: A retrospective pilot study. *Gastric Cancer*. 2015;18(4):698-710. doi:10.1007/s10120-014-0432-5
49. Stein A, Paschold L, Tinteln J, et al. Efficacy of ipilimumab vs FOLFOX in combination with nivolumab and trastuzumab in patients with previously untreated ERBB2-positive esophagogastric adenocarcinoma: The AIO INTEGA randomized clinical trial. *JAMA Oncol*. 2022;8(8):1150-1158. doi:10.1001/jamaoncol.2022.2228
50. Venugopalan AK, Varghese K, Masih D, et al. High concordance of HER2 overexpression by immunohistochemistry on mucosal biopsies and resection in gastric adenocarcinoma. *J Clin Diagn Res*. 2021;15(10):EC16-EC19. doi:10.7860/jcdr/2021/51111.15492
51. Wang DS, Liu ZX, Lu YX, et al. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. *Gut*. 2019;68(7):1152-1161. doi:10.1136/gutjnl-2018-316522
52. Wang H, Li B, Liu Z, et al. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer. *Eur J Cancer*. 2018;88:92-100. doi:10.1016/j.ejca.2017.10.032
53. Wang L, Zhang Q, Ni S, et al. Programmed death-ligand 1 expression in gastric cancer: Correlation with mismatch repair deficiency and HER2-negative status. *Cancer Med*. 2018;7(6):2612-2620. doi:10.1002/cam4.1502
54. Wang X, Wu Y, Song X, et al. Human epidermal growth factor receptor 2 amplification detection by droplet digital polymerase chain reaction in formalin-fixed paraffin-embedded breast and gastric cancer samples. *J Cancer Res Ther*. 2017;13(4):730-734. doi:10.4103/jcrt.JCRT_587_17
55. Wong DD, Kumarasinghe MP, Platten MA, de Boer WB. Concordance of HER2 expression in paired primary and metastatic sites of gastric and gastro-oesophageal junction cancers. *Pathology*. 2015;47(7):641-646. doi:10.1097/PAT.0000000000000323
56. Xu C, Sun M, Jin M, et al. Dual block her2 assessment increased her2 immunohistochemistry positive rate in resected specimens of gastric cancer: A prospective multicenter clinical trial from China. *Diagn Pathol*. 2022;17(1):54. doi:10.1186/s13000-022-01230-7
57. Xu Q, Xu X, Tang H, et al. Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy. *Oncogenesis*. 2023;12(1):21. doi:10.1038/s41389-023-00466-2

Disclaimer

The information, data, and draft recommendations provided by the College of American Pathologists are presented for informational and public feedback purposes only. The draft recommendations and supporting documents will be removed on June 25, 2025.

The draft recommendations along with the public comments received and completed evidence review will be reassessed by the expert panel in order to formulate the final recommendations. These draft materials should not be stored, adapted, or redistributed in any manner.

Please note: comments are not posted automatically. All comments will be posted on a weekly basis beginning June 4, 2025.